A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells

Blood

Volumn 117, Issue 21, 2011, Pages 5692-5700

  Singh, Ajita V ^a   Bandi, Madhavi ^a   Raje, Noopur ^a   Richardson, Paul ^a   Palladino, Michael A ^b   Chauhan, Dharminder ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Nereus Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLINABULIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MITOSIS; MOUSE; MYELOMA CELL; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 79957583553     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-323857     Document Type: Article

References (49)

1. Strobeck M. Multiple myeloma therapies. Nat Rev Drug Discov. 2007;6(3):181-182. (Pubitemid 46344621)
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-598. (Pubitemid 47106630)
3. Dimopoulos MA, Arbuck S, Huber M, et al. Primary therapy of multiple myeloma with paclitaxel (taxol). Ann Oncol. 1994;5(8):757-759. (Pubitemid 24302694)
4. Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). Am J Clin Oncol. 1998;21(6):553-556. (Pubitemid 28558343)
5. Friedenberg WR, Graham D, Greipp P, Blood E, Winston RD. The treatment of multiple myeloma with docetaxel (an ECOG study). Leuk Res. 2003;27(8):751-754. (Pubitemid 36683264)
6. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2002;83(1):21-38. (Pubitemid 34638944)
7. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther. 2003;2(4 suppl 1):S127-S133.
8. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10(2):415-427. (Pubitemid 38173977)
9. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-974. (Pubitemid 43093963)
10. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5(6):436-446. (Pubitemid 40791486)
11. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004;100(12):2491-2499. (Pubitemid 38715753)
12. Monaghan K, Khong T, Smith G, Spencer A. CYT997 causes apoptosis in human multiple myeloma. Invest New Drugs. 2011;29(2):232-238.
13. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 2008;13(2):139-147. (Pubitemid 351342577)
14. Grogan TM, Spier CM, Salmon SE, et al. Pglycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993;81(2):490-495. (Pubitemid 23027169)
15. Tsuruo T, Iida H, Naganuma K, Tsukagoshi S, Sakurai Y. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res. 1983;43(2):808-813. (Pubitemid 13193884)
16. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983;43(6):2905-2910. (Pubitemid 13100565)
17. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 1983;43(5):2267-2272. (Pubitemid 13088772)
18. Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol. 2001;1(4):370-377. (Pubitemid 33585986)
19. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer. 1982;45(1):136-139. (Pubitemid 12207761)
20. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol. 1984;23(4):217-225. (Pubitemid 15072794)
21. Mita MM, Spear MA, Yee LK, et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res. 2010;16(23):5892-5899.
22. National Cancer Institute. PDQ National Cancer Institute Clinical Trials database 2009. http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary= NCI%20Thesaurus&code=C62444.
23. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943-2950.
24. Zhang HY, Gu YY, Li ZG, et al. Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe. Neoplasia. 2004;6(6):802-812.
25. Gorgun G, Calabrese E, Hideshima T, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115(25):5202-5213.
26. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8(5):407-419. (Pubitemid 41579835)
27. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008;111(3):1654-1664. (Pubitemid 351213457)
28. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62(17):4996-5000. (Pubitemid 34984425)
29. Chatterjee M, Rancso C, Stuhmer T, et al. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood. 2008;111(7):3714-3722.
30. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87(3):1104-1112. (Pubitemid 26043538)
31. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5(6):423-435. (Pubitemid 40791485)
32. Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001;21(1A):93-102. (Pubitemid 32267629)
33. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 2002;62(24):7247-7253. (Pubitemid 36025246)
34. Micheletti G, Poli M, Borsotti P, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res. 2003;63(7):1534-1537. (Pubitemid 36373640)
35. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001;61(17):6413-6422. (Pubitemid 32785286)
36. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997;57(10):1829-1834. (Pubitemid 27209705)
37. Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006;17(1):25-31.
38. Wassmann K, Benezra R. Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev. 2001;11(1):83-90. (Pubitemid 32119283)
39. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1995;1(5):506-526.
40. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996;56(4):816-825. (Pubitemid 26055472)
41. Stewart ZA, Mays D, Pietenpol JA. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 1999;59(15):3831-3837. (Pubitemid 29381893)
42. Minn AJ, Boise LH, Thompson CB. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 1996;10(20):2621-2631. (Pubitemid 26357228)
43. Chauhan D, Li G, Podar K, et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004;104(8):2458-2466. (Pubitemid 39331848)
44. Iordanov MS, Wong J, Newton DL, et al. Differential requirement for the stress-activated protein kinase/c-Jun NH(2)-terminal kinase in RNAdamage-induced apoptosis in primary and in immortalized fibroblasts. Mol Cell Biol Res Commun. 2000;4(2):122-128. (Pubitemid 32183174)
45. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37-40. (Pubitemid 32225829)
46. Chauhan D, Li G, Hideshima T, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003;278(20):17593-17596. (Pubitemid 36799359)
47. Lamb JA, Ventura JJ, Hess P, Flavell RA, Davis RJ. JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell. 2003;11(6):1479-1489. (Pubitemid 36776535)
48. Sanchez-Perez T, Ortiz-Ferron G, Lopez-Rivas A. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ. 2010;17(5):883-894.
49. Wang TH, Wang HS, Ichijo H, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem. 1998;273(9):4928-4936. (Pubitemid 28108645)